Literature DB >> 11976272

Relaxation by urocortin of human saphenous veins.

Elena Sanz1, Luis Monge, Nuria Fernández, María Angeles Martínez, Juan B Martínez-León, Godofredo Diéguez, Angel Luis García-Villalón.   

Abstract

Urocortin, an endogenous peptide structurally related to corticotropin-releasing factor (CRF), has potent cardiovascular effects, suggesting that it may be of significance in cardiovascular regulation. The objective of this study was to analyse the effects of urocortin and its action mechanisms on human blood vessels. To this, 3 mm long segments from human saphenous veins were prepared for isometric tension recording in an organ bath. In the segments at basal resting tone, urocortin did not produce any effect, but in the segments precontracted with endothelin-1 (1 - 10 nM), urocortin (1 pM - 10 nM) produced concentration-dependent relaxation. This relaxation was not modified by the inhibitor of nitric oxide synthase NG-nitro-L-arginine methyl ester (L-NAME, 100 microM), but it was potentiated by the cyclo-oxygenase inhibitor meclofenamate (10 microM) and it was reduced by the inhibitors of high-conductance Ca2+-dependent potassium channels tetraethylammonium (TEA, 10 mM) and charybdotoxin (100 nM). These results indicate that human saphenous veins are very sensitive to urocortin, which produces vascular relaxation by a mechanism independent of nitric oxide and dependent of high-conductance Ca2+-dependent potassium channels, and that it may be opposed by the release of vasoconstrictor prostanoids. Therefore, urocortin may be of significance for regulation of the venous circulation in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976272      PMCID: PMC1762105          DOI: 10.1038/sj.bjp.0704670

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

Review 1.  Ion channels and vascular tone.

Authors:  W F Jackson
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

2.  Coronary vasodilation and positive inotropism by urocortin in the isolated rat heart.

Authors:  K Terui; A Higashiyama; N Horiba; K I Furukawa; S Motomura; T Suda
Journal:  J Endocrinol       Date:  2001-04       Impact factor: 4.286

3.  Urocortin stimulates placental adrenocorticotropin and prostaglandin release and myometrial contractility in vitro.

Authors:  F Petraglia; P Florio; C Benedetto; L Marozio; A M Di Blasio; C Ticconi; E Piccione; S Luisi; A R Genazzani; W Vale
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

4.  S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery.

Authors:  N Sogo; C Campanella; D J Webb; I L Megson
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein.

Authors:  Z H Yang; L von Segesser; E Bauer; P Stulz; M Turina; T F Lüscher
Journal:  Circ Res       Date:  1991-01       Impact factor: 17.367

6.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.

Authors:  J Vaughan; C Donaldson; J Bittencourt; M H Perrin; K Lewis; S Sutton; R Chan; A V Turnbull; D Lovejoy; C Rivier
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

7.  Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart.

Authors:  M Perrin; C Donaldson; R Chen; A Blount; T Berggren; L Bilezikjian; P Sawchenko; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Reactivity of the dog cavernous carotid artery. The role of the arterial and venous endothelium.

Authors:  A L García-Villalón; N Fernández; J L García; L Monge; B Gómez; G Diéguez
Journal:  Pflugers Arch       Date:  1993-11       Impact factor: 3.657

9.  Vasodilator actions of urocortin and related peptides in the human perfused placenta in vitro.

Authors:  I M Leitch; A L Boura; C Botti; M A Read; W A Walters; R Smith
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

10.  Cooling effects on nitric oxide production by rabbit ear and femoral arteries during cholinergic stimulation.

Authors:  N Fernández; L Monge; A L García-Villalón; J L García; B Gómez; G Diéguez
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

View more
  8 in total

1.  Mechanisms of the protective effects of urocortin on coronary endothelial function during ischemia-reperfusion in rat isolated hearts.

Authors:  Angel Luis García-Villalón; Yesika María Amezquita; Luis Monge; Nuria Fernández; Belén Climent; Ana Sánchez; Godofredo Diéguez
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

2.  Large-conductance Ca2+-activated K+ channel beta1-subunit knockout mice are not hypertensive.

Authors:  Hui Xu; Hannah Garver; James J Galligan; Gregory D Fink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-03       Impact factor: 4.733

3.  Mechanisms of relaxation by urocortin in renal arteries from male and female rats.

Authors:  Elena Sanz; Luis Monge; Nuria Fernández; Belén Climent; Godofredo Diéguez; Angel Luis Garcia-Villalón
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

4.  CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

5.  [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

Authors:  H Tezval; A S Merseburger; M Seidler; J Serth; M A Kuczyk; M Oelke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 6.  Role of urocortin in pregnancy: An update and future perspectives.

Authors:  Salvatore Giovanni Vitale; Antonio Simone Laganà; Agnese Maria Chiara Rapisarda; Maria Giovanna Scarale; Francesco Corrado; Pietro Cignini; Salvatore Butticè; Diego Rossetti
Journal:  World J Clin Cases       Date:  2016-07-16       Impact factor: 1.337

7.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

8.  Vascular effects of urocortins 2 and 3 in healthy volunteers.

Authors:  Sowmya Venkatasubramanian; Megan E Griffiths; Steven G McLean; Mark R Miller; Rosa Luo; Ninian N Lang; David E Newby
Journal:  J Am Heart Assoc       Date:  2013-01-31       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.